蒋晞 - 浙江大学

个人简介

蒋晞博士，浙江大学医学院研究员、博士生导师。课题组主要研究肿瘤，特别是白血病的表观遗传学调节机制，以及针对表观遗传学机制的临床转化应用。研究成果和代表性论文如下： 1、阐明一系列微核糖核酸在白血病中的作用机制，采用靶向特异性纳米载体运输抑癌微核糖核酸治疗白血病（Nat Commun, 2016; Cancer Res, 2016; Cancer Cell, 2012; Proc Natl Acad Sci, 2012）； 2、揭示TET1介导的DNA 5-羟甲基胞嘧啶（5-hydroxymethylcytosine; 5hmC）修饰在白血病中的作用和机制，通过高通量小分子化合物筛选找寻TET1表达抑制剂治疗白血病（Nat Commun, 2017; Nat Commun, 2016; Proc Natl Acad Sci, 2013）； 3、揭示RNA N6-甲基腺苷（N6-Methyladenosine; m6A）修饰在造血分化和白血病中的作用机制以及治疗应用（Cell, 2018; Cell Stem Cell, 2018; Cancer Cell, 2017）。教育工作经历 2000-2005 复旦大学医学院学士 2005-2010 复旦大学医学院博士（导师：马兰教授） 2010-2014 美国芝加哥大学（University of Chicago）博士后（导师：美国科学院院士Janet D. Rowley教授和陈建军教授） 2015-2017 美国辛辛那提大学（University of Cincinnati）助理教授（研究型）（Assistant Professor-Research） 2017-2018 美国希望城国家医疗中心（Beckman Research Institute of City of Hope）研究型助理教授（Assistant Research Professor, Step III） 2018- 浙江大学医学院研究员、博士生导师

研究领域

1、研究DNA和RNA 修饰在白血病化疗反应中的作用和调节机制； 2、探寻针对致癌DNA和RNA调控因子最佳靶位点的小分子拮抗剂； 3、筛选直接或间接作用于DNA和RNA修饰、且具潜在AML治疗作用的小分子化合物。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

(1) Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki A, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J. (2018) R-2HG exhibits anti-tumor activity by targeting FTO/MYC signaling. Cell. 11; 90-105. PMID: 29249359. IF=30.4 (2) Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore L, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 22; 191-205. PMID: 29290617. IF=22.4 (3) Huang H, Weng H, Sun W, Qin X, Shi H, Zhao BS, Mesquita A, Yuan CL, Hu YC, Hüttelmaier S, Strong J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Qu L, Guan JL, He C, Yang J, Chen J. Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability. Nat Cell Biol. 20； 285-295. PMID: 29476152. IF=20.1 (4) Jiang Xi#, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J. (2017) Targeted inhibition of TET1 transcription as a potent therapeutic strategy for acute myeloid leukemia. Nat Commun. 13; 2099. PMID: 29235481. IF=12.1 (5) Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, Qin X, Jin J, Chen J, Jiang Xi#. (2017) ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 12; 1853. PMID: 28500307. IF=4.3 (6) Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 31; 127-141. PMID: 28017614. IF=27.4 (7) Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. (2016) miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 26; 11452. PMID: 27116251. IF=12.1 (8) Jiang X#, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. (2016) Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 76; 4470-4480. PMID: 27280396. IF=9.3 (9) Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. (2016) PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 76, 619-629. PMID: 26747896. IF=9.3 (10) Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. (2016) Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 372, 157-165. PMID: 26791235. IF=6.4 (11) Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. (2015) Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 126, 2005-2015. PMID: 26361793. IF=13.2 (12) He Y, Jiang X and Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 33, 3887-93. PMCID: Pending. IF=8.5 (13) Huang H*, Jiang X*, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C and Chen J. (2013) TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 110, 11994-11999. PMCID: PMC3718141. IF=9.7 (14) Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews J, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C and Chen J. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 16, 524-535. PMCID: PMC3480215. IF=27.4 (15) Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD and Chen J. (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 20, 19397-19402. PMCID: PMC3511140. IF=9.7 (16) Li Z*, Huang H*, Li Y*, Jiang X*, Chen P, Arnovitz S, Radmacher MD, Maharry K, Elkahloun A, Yang X, He C, He M, Zhang Z, Dohner K, Neilly MB, Price C, Lussier YA, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Bullinger L, Valk PJ, Delwel R, Lowenberg B, Liu PP, Marcucci G, Bloomfield CD, Rowley JD and Chen J. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 119, 2314-2324. PMCID: PMC3311258. IF=13.2 (17) Jiang X and Chen J. (2012) miR-150: targeting MLL leukemia. Oncotarget. 3, 1268-1269. PMCID: PMC3717789. IF=5.2 (18) Jiang X, Yang P and Ma L. (2009) Kinase activity-independent regulation of Cyclin pathway by GRK2 Is essential for zebrafish early development. Proc Natl Acad Sci USA. 106, 10183-10188. PMCID: PMC2700943. IF=9.7